Fulgent Genetics' 15min chart indicates Bollinger Bands expanding upward, KDJ golden cross.

Fulgent Genetics' 15-minute chart indicates a significant upward trend, as evidenced by the expanding Bollinger Bands and the recent KDJ Golden Cross on April 22, 2025, at 11:15. This suggests that the market is being driven by buyers, and the momentum of the stock price is shifting towards the upside, with the potential for further increase.

Fulgent Genetics Inc. (FLGT) reported a robust fourth quarter, with a 14% year-over-year growth, and set its 2025 guidance on February 28, 2025. The company's full-year core revenue reached $281.2 million, marking a 7% increase over 2023. The fourth quarter revenue climbed to $76.2 million, up from $70.5 million in the same period last year [1].

Despite the strong financial performance, Fulgent Genetics reported a GAAP loss of $42.7 million for 2024, translating to a loss of $1.41 per share. However, the company's non-GAAP income for the year was $15 million, or $0.49 per share. The fourth quarter GAAP gross margin was 41.8%, while the non-GAAP gross margin was 44.2%. The company's adjusted EBITDA for the quarter was $774,000, and non-GAAP income was $1.2 million, or $0.04 per share [1].

Looking ahead, Fulgent Genetics expects core revenue of approximately $310 million in 2025, representing a 10% year-over-year growth. The company anticipates a non-GAAP gross margin of slightly exceeding 40% and a non-GAAP operating margin of approximately minus 15%. The expected GAAP EPS for 2025 is a loss of approximately $1.95 per share, while the expected non-GAAP loss is $0.65 per share. The company expects a cash position of approximately $780 million at the end of 2025 [1].

The company's stock has shown significant upward momentum, as indicated by the expanding Bollinger Bands and the recent KDJ Golden Cross on April 22, 2025, at 11:15. This suggests that the market is being driven by buyers, and the momentum of the stock price is shifting towards the upside, with the potential for further increase [2].

Fulgent Genetics has made significant advancements in therapeutic development, including the initiation of Phase 2 clinical trials for FID-007 and the clearance of an investigational new drug application for FID-022. The company has also launched new products like the exome and genome RISE, which could potentially increase diagnostic yield by as much as 30%. Furthermore, Fulgent Genetics has formed a new partnership with Foundation Medicine, which is expected to enhance their precision diagnostics offerings [1].

However, the company's biopharma services experience large swings quarter-to-quarter, indicating variability and potential instability. Fulgent Genetics anticipates a cash burn of approximately $25 million for their therapeutics development business in 2025. The company has not included potential revenue from new partnerships, such as with Foundation Medicine, in their 2025 guidance, indicating uncertainty in realizing these opportunities [1].

References:
[1] https://finance.yahoo.com/news/fulgent-genetics-inc-flgt-q4-203712496.html
[2] GuruFocus